Intracerebroventricular Enzyme Replacement Therapy in Patients with Neuropathic Form of Mucopolysaccharidosis Type II: to Help Practicing Physician
https://doi.org/10.15690/vsp.v23i4.2785
Abstract
Mucopolysaccharidosis type II (Hunter syndrome, MPS II) is a rare hereditary disease from the group of hereditary metabolic diseases. There are neuropathic and non-neuropathic forms of this disease. The neuropathic form is most common and leads to severe cognitive impairment and progressive damage of central nervous system. Nowadays, early diagnosis and timely initiation of pathogenetic therapy in patients with orphan diseases is the crucial problem of modern pediatrics. Intracerebroventricular administration of idursulfase beta is one of the promising treatment options in patients with neuropathic form of MPS II as it prevents severe complications development. The study of new pathogenetic therapy methods for rare hereditary diseases will help doctors of pediatric specialties to route patient correctly in timely manner to receive all the necessary treatment.
About the Authors
Nataliya V. Zhurkova
Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Lecturing for pharmaceutical companies Takeda, Sanofi Aventis Group, AstraZeneca, Chiesi pharmaceuticals, Nutricia.
Nato D. Vashakmadze
Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery ; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Lecturing for pharmaceutical companies Takeda, Sanofi Aventis Group, Biomarin, Nanolek, Chiesi pharmaceuticals, Nutricia, AstraZeneca.
Georgiy A. Karkashadze
Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests.
Elena V. Kaytukova
Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery ; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests.
References
1. Resolution on the results of the expert council. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2024;21(1):66–69. (In Russ). doi: https://doi.org/10.15690/pf.v21i1.2657
2. Seo JH, Okuyama T, Shapiro E, et al. Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course. Mol Genet Metab Rep. 2020;24:1006–1030. doi: https://doi.org/10.1016/j.ymgmr.2020.100630
3. D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci. 2020;21(4):1258–1263. doi: https://doi.org/10.3390/ijms21041258
4. Stapleton M, Kubaski F, Mason RW, et al. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5(4):295–307. doi: https://doi.org/10.1080/21678707.2017.1296761
5. Barone R, Pellico A, Pittalà A, Gasperini S. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses. Ital J Pediatr. 2018;16(44):121–127. doi: https://doi.org/10.1186/s13052-018-0561-2
6. Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr. 2011;159(2):320–326. doi: https://doi.org/10.1016/j.jpeds.2011.03.019
7. Vollebregt AAM, Hoogeveen-Westerveld M, Kroos MA, et al. Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype. Dev Med Child Neurol. 2017;59(10):1063–1070. doi: 10.1111/dmcn.13467
8. Rykunova AI, Vashakmadze ND, Zhurkova NV, et al. Structural Parameters of the Brain and Bone Structures of the Head and Neck in Patients with Various Types of Mucopolysaccharidoses According to Magnetic Resonance Imaging of the Brain. Annals of the Russian Academy of Medical Sciences. 2023;78(5):431–440. (In Russ). doi: https://doi.org/10.15690/vramn11613
9. Kubaski F, Yabe H, Suzuki Y, et al. Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. Biol Blood Marrow Transplant. 2017;23(10):1795–1803. doi: https://doi.org/10.1016/j.bbmt.2017.06.020
10. Hoshina H, Shimada Y, Higuchi T, et al. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2- sulfatase in mucopolysaccharidosis type II. Mol Genet Metab. 2018;123(2):118–122. doi: https://doi.org/10.1016/j.ymgme.2017.12.428
11. Muenzer J, Burton BK, Harmatz P, et al. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study. Mol Genet Metab. 2022;137(1-2): 127–139. doi: https://doi.org/10.1016/j.ymgme.2022.07.017
12. Sohn YB, Ko AR, Seong MR, et al. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology. J Inherit Metab Dis. 2018;41(6):1235–1246. doi: https://doi.org/10.1007/s10545-018-0221-0
13. Seo JH, Kosuga M, Hamazaki T, et al. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study. Mol Genet Metab. 2023;140(4):107709. doi: https://doi.org/10.1016/j.ymgme.2023.107709
14. Seo JH, Kosuga M, Hamazaki T, et al. Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II. Mol Ther Methods Clin Dev. 2021;21:67–75. doi: https://doi.org/10.1016/j.omtm.2021.02.018
15. Ozerov SS, Melnikov AV, Samarin AE, et al. Ommaya reservoir for intraventricular chemotherapy of children with neuro-oncological and oncohematological diseases: Design history, implantation technology, and experience gained at the Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev. Pediatric Hematology/ Oncology and Immunopathology. 2015;14(4):5–9. (In Russ). doi: https://doi.org/10.24287/1726-1708-2015-14-4-5-9
16. Вашакмадзе Н.Д. Мультидисциплинарные принципы ведения детей с мукоVashakmadze ND.Mul’tidistsiplinarnye printsipy vedeniya detei s mukopolisakharidozami v povyshenii effektivnosti ikh diagnostiki i lecheniya. [abstract of dissertation]. Yekaterinburg; 2019. 47 p. (In Russ).
17. Mukopolisaharidos, tip II: Clinical guidelines. Union of Pediatricians of Russia; Association of Medical Geneticists. Ministry of Health of Russian Federation; 2021. 74 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/recomend/392_2. Ссылка активна на 12.08.2024.
Review
For citations:
Zhurkova N.V., Vashakmadze N.D., Karkashadze G.A., Kaytukova E.V. Intracerebroventricular Enzyme Replacement Therapy in Patients with Neuropathic Form of Mucopolysaccharidosis Type II: to Help Practicing Physician. Current Pediatrics. 2024;23(4):266-270. (In Russ.) https://doi.org/10.15690/vsp.v23i4.2785
Views:
223
Email this article 
